Andrew Bomback, MD, MPH, is an assistant professor of medicine at Columbia University Medical Center.
Andrew Bomback, MD, MPH, opens the segment by asking Gerald Appel, MD, how he defines a non-responder in fibrillary glomerulonephritis (FGN) in practice, how long patients should remain on therapy, and what numbers signal that treatment is not working.
Fibrillary glomerulonephritis (FGN) remains one of the least-studied glomerular diseases in nephrology, accounting for less than 1% of kidney biopsies and offering clinicians few evidence-based treatment options.
Bomback, MD, MPH answers HCPLive’s questions regarding phase 3 VALIANT results and pegcetacoplan’s therapeutic ability in C3G and IC-MPGN.
A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.
